Tissue inhibitor of metalloproteinase 4 in aqueous humor of patients with primary open angle glaucoma, pseudoexfoliation syndrome and pseudoexfoliative glaucoma and its role in proteolysis imbalance

BMC Ophthalmology

Research Article

Ioannis Tentes¹  Alexandros Kortsaris¹  Nikitas Fountoulakis²  Vassilios P Kozobolis²  Antonios Aristeidou²  Georgios Labiris²  Andreas Katsanos³ 

[1] Department of Biochemistry, Democritus University of Thrace, Alexandroupolis, Greece;Department of Ophthalmology, Democritus University of Thrace, Alexandroupolis, Greece;Eye Institute of Thrace, Alexandroupolis, Greece;Department of Ophthalmology, University of Ioannina, Ioannina, Greece;

关键词: Glaucoma;    Pseudoexfoliation;    Metalloproteinases;    TIMP4;    TIMP/MMP ratios;   

DOI  :  10.1186/1471-2415-13-69

 received in 2013-04-09, accepted in 2013-10-29,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundTo quantify the levels of tissue inhibitor of metalloproteinase 4 (TIMP4) and its ratios with free metalloproteinases (MMP) in the aqueous humor of patients with primary open angle glaucoma (POAG), pseudoexfoliation syndrome (PXS) and pseudoexfoliative glaucoma (PXG) and to evaluate a possible imbalance between MMPs and TIMPs in these samples.MethodsFree MMP2, MMP3, MMP9, TIMP1, TIMP2, TIMP4 concentrations and active levels of MMP2 and MMP3 were determined with immunoassay ELISA and activity assay kits in 168 aqueous samples.ResultsTIMP4 was elevated in glaucoma patients(POAG: 0.95 ± 0.49 PXG: 1.28 ± 1.38 pg/ml. p < 0.001). POAG, PXS and PXG samples demonstrated higher MMP2, TIMP1 and TIMP2 concentrations (p < 0.001). Samples from the PXS and PXG groups had a lower total/active MMP2 ratio (p < 0.004 and p < 0.008 respectively). Stoichiometric analysis showed an overbalance of TIMPsover MMPs in both POAG & PXG groups,especially of TIMP4.ConclusionTIMP4 elevation is a novel finding in glaucomatous eyes. A disregulation of extracellular matrix homeostasis is suggested in POAG, PXS and PXG.

【 授权许可】

CC BY   
© Fountoulakis et al.; licensee BioMed Central Ltd. 2013